SAB Biotherapeutics Warrant
SABSW
13 hedge funds and large institutions have $376K invested in SAB Biotherapeutics Warrant in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.19% less ownership
Funds ownership: 4.15% → 3.95% (-0.19%)
2% less capital invested
Capital invested by funds: $383K → $376K (-$6.82K)
19% less funds holding
Funds holding: 16 → 13 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$9.27K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$681 |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$261 |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$65 |
| 5 |
Jane Street
New York
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$27K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$10K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1K |
| 4 |
HF
HRT Financial
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $318K | +$9.27K | +152,000 | +39% |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $23K | -$10K | -164,590 | -25% |
|
3
Balyasny Asset Management
Chicago,
Illinois
| $16.7K | – | – | – |
|
4
Morgan Stanley
New York
| $7K | – | – | – |
|
|
YCM
5
Yakira Capital Management
Westport,
Connecticut
| $5.1K | – | – | – |
|
|
EPM
6
Equitec Proprietary Markets
Chicago,
Illinois
| $2.12K | – | – | – |
|
7
Walleye Capital
New York
| $1.09K | – | – | – |
|
|
FTUS
8
Flow Traders U.S.
New York
| $1K | +$261 | +4,274 | +36% |
|
9
Walleye Trading
New York
| $729 | – | – | – |
|
|
WAM
10
Wolverine Asset Management
Chicago,
Illinois
| $601 | +$681 | +11,169 | +689% |
|
|
11
Jane Street
New York
| $512 | +$24 | +400 | +4% |
|
|
RCM
12
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| – | -$27K | -38,927 | Closed |
|
|
HF
13
HRT Financial
New York
| – | -$1K | -23,756 | Closed |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$1K | -19,905 | Closed |
|
|
NA
15
NewEdge Advisors
New Orleans,
Louisiana
| – | +$65 | +1,072 | New |
|
SABSW Hedge Fund Activity: Q4 2022 in Review
13 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2022, worth a combined $376K — down 1.8% from $383K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SABSW and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was LMR Partners, adding an estimated $9.27K. The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $27K sold.
- 13 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2022, down from 16 in Q3 2022.
- Funds reported $376K of SAB Biotherapeutics Warrant stock for Q4 2022, down 1.8% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q4 2022 and 4 closed out, a net change of -3 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q4 2022 was LMR Partners, an estimated $9.27K added.
- The largest SAB Biotherapeutics Warrant seller in Q4 2022 was Radcliffe Capital Management, an estimated $27K sold.
Based on aggregated 13F filings for Q4 2022.